High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft.
Cairoli
Roberto
R
Grillo
Giovanni
G
Tedeschi
Alessandra
A
D'Avanzo
Giovanna
G
Marenco
Paola
P
Morra
Enrica
E
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016465:Bone Marrow Purging / Q000009:adverse effects; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D000069283:Rituximab; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab